The Latin America, Middle East and Africa Non-invasive Prenatal Testing (NIPT) Market would witness market growth of 21.4% CAGR during the forecast period (2023-2030).
This cutting-edge technology allows for ultra-sensitive and accurate analysis of cell-free DNA. It can potentially identify rare genetic mutations and structural chromosomal abnormalities, further increasing the diagnostic power of NIPT. Innovations are being made to enhance the foetal fraction in maternal blood, which can improve the accuracy of NIPT results, especially in cases where the foetal fraction is low. Some researchers are exploring the integration of multinomic profiling, which involves analyzing various molecular markers in maternal blood, such as microRNA, proteins, and DNA. This multi-faceted approach can provide a more comprehensive view of foetal health.
NIPT is used not only for genetic screening but also for the early detection of pregnancy complications like preeclampsia and gestational diabetes. This expanded application can help healthcare providers intervene earlier and improve pregnancy outcomes. Advances in telehealth and remote monitoring technology allow pregnant individuals to undergo NIPT and receive results from the comfort of their homes, reducing the need for in-person appointments. Some researchers are looking into how NIPT may be used to evaluate how environmental and lifestyle factors affect foetal development and reveal how they might affect health consequences.
The Brazilian government has implemented several initiatives and programs to boost healthcare investments and improve the healthcare system in the country. Unified Health System (Sistema Único de Saúde
Based on Product, the market is segmented into Consumables & Reagents, and Instruments. Based on Application, the market is segmented into Trisomy, Microdeletion Syndrome, and Others. Based on End User, the market is segmented into Diagnostic Laboratories, Hospitals & Clinics. Based on Technology, the market is segmented into Next Generation Sequencing (NGS), Microarray, Polymerase Chain Reaction (PCR), and Rolling Circular Amplification. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Illumina, Inc., Natera Inc., F. Hoffmann-La Roche Ltd., PerkinElmer, Inc., Laboratory Corporation of America Holdings, Eurofins Scientific SE, Thermo Fisher Scientific, Inc., GE HealthCare Technologies, Inc., Agilent Technologies, Inc., and Pacific Biosciences of California, Inc.
This cutting-edge technology allows for ultra-sensitive and accurate analysis of cell-free DNA. It can potentially identify rare genetic mutations and structural chromosomal abnormalities, further increasing the diagnostic power of NIPT. Innovations are being made to enhance the foetal fraction in maternal blood, which can improve the accuracy of NIPT results, especially in cases where the foetal fraction is low. Some researchers are exploring the integration of multinomic profiling, which involves analyzing various molecular markers in maternal blood, such as microRNA, proteins, and DNA. This multi-faceted approach can provide a more comprehensive view of foetal health.
NIPT is used not only for genetic screening but also for the early detection of pregnancy complications like preeclampsia and gestational diabetes. This expanded application can help healthcare providers intervene earlier and improve pregnancy outcomes. Advances in telehealth and remote monitoring technology allow pregnant individuals to undergo NIPT and receive results from the comfort of their homes, reducing the need for in-person appointments. Some researchers are looking into how NIPT may be used to evaluate how environmental and lifestyle factors affect foetal development and reveal how they might affect health consequences.
The Brazilian government has implemented several initiatives and programs to boost healthcare investments and improve the healthcare system in the country. Unified Health System (Sistema Único de Saúde
- SUS) is Brazil's public healthcare system, providing free healthcare services to all citizens. The government continuously invests in SUS to improve infrastructure, expand healthcare coverage, and increase the availability of essential medicines. Therefore, the increase in healthcare investments across LAMEA region countries poses lucrative prospects for the growth of the regional market.
Based on Product, the market is segmented into Consumables & Reagents, and Instruments. Based on Application, the market is segmented into Trisomy, Microdeletion Syndrome, and Others. Based on End User, the market is segmented into Diagnostic Laboratories, Hospitals & Clinics. Based on Technology, the market is segmented into Next Generation Sequencing (NGS), Microarray, Polymerase Chain Reaction (PCR), and Rolling Circular Amplification. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Illumina, Inc., Natera Inc., F. Hoffmann-La Roche Ltd., PerkinElmer, Inc., Laboratory Corporation of America Holdings, Eurofins Scientific SE, Thermo Fisher Scientific, Inc., GE HealthCare Technologies, Inc., Agilent Technologies, Inc., and Pacific Biosciences of California, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Product- Consumables & Reagents
- Instruments
- Trisomy
- Microdeletion Syndrome
- Others
- Diagnostic Laboratories
- Hospitals & Clinics
- Next Generation Sequencing (NGS)
- Microarray
- Polymerase Chain Reaction (PCR)
- Rolling Circular Amplification
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Illumina, Inc.
- Natera Inc.
- F. Hoffmann-La Roche Ltd.
- PerkinElmer, Inc.
- Laboratory Corporation of America Holdings
- Eurofins Scientific SE
- Thermo Fisher Scientific, Inc.
- GE HealthCare Technologies, Inc.
- Agilent Technologies, Inc.
- Pacific Biosciences of California, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. LAMEA Non-invasive Prenatal Testing (NIPT) Market by Product
Chapter 5. LAMEA Non-invasive Prenatal Testing (NIPT) Market by Application
Chapter 6. LAMEA Non-invasive Prenatal Testing (NIPT) Market by End User
Chapter 7. LAMEA Non-invasive Prenatal Testing (NIPT) Market by Technology
Chapter 8. LAMEA Non-invasive Prenatal Testing (NIPT) Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- Illumina, Inc.
- Natera Inc.
- F. Hoffmann-La Roche Ltd.
- PerkinElmer, Inc.
- Laboratory Corporation of America Holdings
- Eurofins Scientific SE
- Thermo Fisher Scientific, Inc.
- GE HealthCare Technologies, Inc.
- Agilent Technologies, Inc.
- Pacific Biosciences of California, Inc.
Methodology
LOADING...
